|
[1]
|
Gene therapy for Parkinson’s Disease and Ethical Challenges: A Systematic Review
Advances in Parkinson's Disease,
2023
DOI:10.4236/apd.2023.122002
|
|
|
|
|
[2]
|
Role of luteolin in overcoming Parkinson's disease
BioFactors,
2021
DOI:10.1002/biof.1706
|
|
|
|
|
[3]
|
Role of luteolin in overcoming Parkinson's disease
BioFactors,
2021
DOI:10.1002/biof.1706
|
|
|
|
|
[4]
|
Association of small intestinal bacterial overgrowth with Parkinson’s disease: a systematic review and meta-analysis
Gut Pathogens,
2021
DOI:10.1186/s13099-021-00420-w
|
|
|
|
|
[5]
|
Improvement of oral function and hygiene in Parkinson's disease: A randomised controlled clinical trial
Journal of Oral Rehabilitation,
2020
DOI:10.1111/joor.12924
|
|
|
|
|
[6]
|
Improvement of oral function and hygiene in Parkinson's disease: A randomised controlled clinical trial
Journal of Oral Rehabilitation,
2020
DOI:10.1111/joor.12924
|
|
|
|
|
[7]
|
The ability of three African herbal remedies to offer protection against an in vitro model of Parkinson’s disease
South African Journal of Botany,
2019
DOI:10.1016/j.sajb.2019.01.033
|
|
|
|
|
[8]
|
In Vitro and In Vivo Neuroprotective Effects of Stellettin B Through Anti-Apoptosis and the Nrf2/HO-1 Pathway
Marine Drugs,
2019
DOI:10.3390/md17060315
|
|
|
|
|
[9]
|
Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy,
2019
DOI:10.2174/1574362413666180312125419
|
|
|
|
|
[10]
|
Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease
Neurological Sciences,
2018
DOI:10.1007/s10072-018-3628-3
|
|
|
|
|
[11]
|
The Emerging Role of Energy Metabolism and Neuroprotective Strategies in Parkinson's Disease
Frontiers in Aging Neuroscience,
2018
DOI:10.3389/fnagi.2018.00301
|
|
|
|
|
[12]
|
Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
Pharmacology Research & Perspectives,
2016
DOI:10.1002/prp2.251
|
|
|
|
|
[13]
|
Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
Pharmacology Research & Perspectives,
2016
DOI:10.1002/prp2.251
|
|
|
|